Canagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels.
The Food and Drug Administration has approved the use of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for use in Type II diabetics. These are a relatively new addition to the armamentaria of diabetes management. Postmarketing surveillance is a witn.....